PharmiWeb.com - Global Pharma News & Resources
17-Sep-2019

Biofrontera AG: Biofrontera to present at the Baader Investment Conference

DGAP-News: Biofrontera AG / Key word(s): Conference

17.09.2019 / 15:45
The issuer is solely responsible for the content of this announcement.


Biofrontera to present at the Baader Investment Conference

Leverkusen, Germany, September 17, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, announced that Prof. Dr. Hermann Lübbert, Biofrontera's CEO, will be presenting at the Baader Investment Conference. The conference will take place from September 23-27, 2019 at the Sofitel Munich Bayerpost in Munich, Germany.

Biofrontera's management team will be available for one-on-one meetings with investors who are registered to attend the event.

Details for the presentation are as follows:

Date: Friday, September 27, 2019
Time: 10:00 AM CEST
Venue: Sofitel Munich Bayerpost, Forum 2
-End-

For enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer


+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen

+44 (0) 207 229 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets Xepi, a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.



17.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 875007

 
End of News DGAP News Service

Editor Details

Last Updated: 17-Sep-2019